Mira PharmaceuticalsMIRA -0.26%13 Pretax Margin % is % as of Mar. 2026. GuruFocus rates MIRA with a GF Score™ of 13/100. The stock has 1 warning sign investors should review. Among 954 Drug Manufacturers companies, Mira Pharmaceuticals ranks worse than 104821.7% on this metric.
The historical rank and industry rank for Mira Pharmaceuticals's Pretax Margin % or its related term are showing as below:
MIRA's Pretax Margin % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 7.295 * Ranked among companies with meaningful Pretax Margin % only.
Mira Pharmaceuticals (NAS:MIRA) Pretax Margin % Explanation
The pretax margin, as know as pretax profit margin, is widely used to measure the operating efficiency of a company before deducting taxes.
The pretax margin is sometimes preferred over the net margin as tax expenditures can make profitability comparisons between companies misleading.
It is a useful tool to compare companies operating in the same sector and less effective when comparing companies from other sectors as each industry generally has different operating expenses and sales patterns.
The long term trend of the pretax margin is a good indicator of the competitiveness and health of the business.
Mira Pharmaceuticals Pretax Margin % Related Terms
Mira Pharmaceuticals Pretax Margin % Historical Data
* Premium members only.
The historical data trend for Mira Pharmaceuticals's Pretax Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MIRA vs NSRX, SCLX, MDCX: Pretax Margin % Comparison
For the Drug Manufacturers - General subindustry, Mira Pharmaceuticals's Pretax Margin %, along with its competitors' market caps and Pretax Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Mira Pharmaceuticals Pretax Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Mira Pharmaceuticals's Pretax Margin % distribution charts can be found below:
* The bar in red indicates where Mira Pharmaceuticals's Pretax Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Mira Pharmaceuticals (MIRA) has a Pretax Margin % of % as of Mar. 2026. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Mira Pharmaceuticals and its competitors. According to the industry distribution chart, Mira Pharmaceuticals ranks #999999 out of 954 companies in the Drug Manufacturers industry.
Is Mira Pharmaceuticals' Pretax Margin % too high?
Mira Pharmaceuticals' current Pretax Margin % is %. Based on the distribution chart, Mira Pharmaceuticals ranks #999999 out of 954 companies in the Drug Manufacturers industry, which is in the bottom quartile relative to peers. Overall, Mira Pharmaceuticals has a GF Score™ of 13/100, reflecting its overall financial health beyond just this single metric.
How does Mira Pharmaceuticals' Pretax Margin % compare to NSRX and SCLX?
According to the Drug Manufacturers industry distribution chart, Mira Pharmaceuticals ranks #999999 out of 954 companies for Pretax Margin %. This places Mira Pharmaceuticals in the lower half of its industry. The industry median Pretax Margin % is 7.30. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Pretax Margin % for a Drug Manufacturers company?
The median Pretax Margin % among Drug Manufacturers companies is 7.30, based on 954 companies in the industry. Companies in the top quartile (top 25%) have a Pretax Margin % significantly above this median, while those in the bottom quartile fall well below. However, Pretax Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Pretax Margin % mean?
A high Pretax Margin % can signal that a stock is expensive relative to its fundamentals. Pre-Tax margin is the ratio of total pre-tax income to net sales. View historical data on Mira Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median Pretax Margin % is 7.30 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Mira Pharmaceuticals's current Pretax Margin % is %. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mira Pharmaceuticals stock overvalued right now?
Mira Pharmaceuticals (MIRA) has a current Pretax Margin % of %. The current Pretax Margin % is %. Mira Pharmaceuticals' overall GF Score™ is 13/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Pretax Margin % calculated?
Pretax Margin % is calculated from a company's financial statements. For Mira Pharmaceuticals (MIRA), the current Pretax Margin % is % as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mira Pharmaceuticals Inc is a clinical-stage pharmaceutical development company focused on developing novel oral small-molecule therapeutics for neurologic, neuropsychiatric, metabolic, and inflammatory disorders. The company's pipeline includes three product candidates: Ketamir-2, MIRA-55, and SKNY-1, three drug candidates designed to address unmet medical needs across neuropathic and inflammatory pain, central nervous system disorders, and metabolic and behavioral conditions. The company operates as a single operating and reportable segment.
13GF Score
Get the complete analysis for MIRA
Pretax Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MIRA has been successfully added to your 
